One Min. That is explaining NO. But now is a explaination on L-
Arginine.

A Report On Arginine
By Harry Elwardt, N.D., PhD.
"... A few grams of prevention is worth a ton of cure." 1
So just what is Nitric Oxide (NO)? Over 20,000 articles in the medical
literature since 1980 attest that "absolutely everything in the body
depends
on it." Its function in human physiology is so important that the
American
Academy of Science named Nitric Oxide the "Molecule of the year" in
1992. The Nobel Peace prize in Medicine was awarded to scientists who
began the research on Nitric Oxide in 1998 and now NO has been
referred
to as "The Molecule of the Millennium". Dr. Jonathan S. Stamler, a
professor of medicine at Duke University Medical Center, put it best
when
he said of Nitric Oxide:
"It does everything, everywhere. You cannot name a major cellular
response or
physiological effect in which [Nitric Oxide] is not implicated today.
It's involved in
complex behavioral changes in the brain, airway relaxation, beating of
the heart,
dilation of blood vessels, regulation of intestinal movement, function
of blood
cells, the immune system, even how fingers and arms move."
There are three types of NO. Endothelial-derived NO diffuses out of
endothelial cells
(cells lining arteries and veins) and into smooth muscle cells of
arteries enhancing
relaxation and other properties of vascular physiology.
Endothelial-derived NO also functions in platelets (blood cells
responsible for blood clots)
to inhibit aggregation or blood clotting. Brain-derived NO affects
several types of nerve
cells and appears to be important in neurotransmitter pathways in both
the central as well
as peripheral nervous system and regulates the production and release
of many
hormones. Macrophage-derived NO is important in the immune system.
This type of NO
helps macrophages (a type of immune cell) kill bacteria and tumor
cells. So, NO is
important to the nervous system, the immune system and the vascular
system, which
supplies nutrients to all parts of the body. Arginine, when combined
with Oxygen, forms
NO. Arginine, as found in Ark1? is the source of all forms of NO.2, 3
NO decreases with age 4, 5, 6, various age related conditions and many
medications7,8.
Among the most common disease states to affect NO and therefore sexual
function are:
? Diabetes
? Heart disease
? Hypertension (high blood pressure)
? Peripheral Vascular Disease
? Neurological Damage
? Peptic Ulcer
? Arthritis
? Allergy
? Low HDL
2
? Some of the most common drugs affecting NO and/or sexual functions
are
antidepressants - many common drugs like Elavil?, Prozac?. Paxil?,
Zoloft?, etc.
? Anti-anxiety drugs, including Xanax? and Valium?
? Anti-psychotic drugs
? Blood Pressure medications
? Other Cardiac drugs, like lanoxin or other drugs that affect cardiac
rhythm
? Anti-heartburn drugs like Tagamet? and Zantac?
? Opioids especially chronic use of legal (e.g., Lortab?, codeine,
etc.) and illegal
(e.g., heroin) narcotics and pain medicines
? Alcohol, especially chronic use
? Tobacco
The use of many of these drugs and the incidence of most of this
disease conditions
increase after the age of 40. Obviously it is also the age group most
likely to benefit from
the use of Ark1?, though any age group can benefit. The 40 and above
age group is
also the most likely age group (both men and women) to want to use
Ark1? for the
treatment of sexual dysfunction. In the genital tissue, NO triggers
the release of c-GMP,
which is a molecule that causes engorgement of this tissue. The
arginine found in Ark1?
releases NO to make sure there is plenty of c-GMP. Viagra, on the
other hand, is a drug
that blocks an enzyme to make sure there is plenty of c-GMP. Arginine
has been shown
to be a safe and effective alternative to Viagra?. Viagra? has been
reported to be safe;
however, the FDA public records suggest the opposite. These records
reported that
between April of 1998 and May of 1999 there were 1,473 adverse events
including 255
serious heart rhythm disturbances, 53 episodes of congestive heart
failure (weakened
heart) 119 strokes, 517 heart attacks and 522 deaths.9
Every major disease process today is directly or indirectly related to
lack of NO.
Diabetes, Hypertension, Hyperlipidemia, Hypercholesterolemia, Cancer,
Peripheral
Vascular Disease, Coronary Artery Disease, Sickle Cell, Scleroderma,
Renal
Failure, Pulmonary Hypertension and Atherosclerosis are all associated
with
decreased levels of NO. (With the exception of cancer, where NO
functions in the
immune system, most of these disease processes involve the vascular
system and
endothelial derived NO).
The primary function of endothelial derived NO is vascular
homeostasis, or balance. NO
maintains vascular health by enhancing endothelial reactivity. The
endothelium is the
inner lining of the blood vessels and as long as the endothelium
remains reactive, they
are supple, pliable and flexible. They are able to respond
appropriately to the various
changes that occur in blood vessels in the course of normal and
abnormal physiology,
when NO decreases, the vessels become stiff and rigid.
This is called atherosclerosis or hardening of the arteries. When we
develop
atherosclerosis, the results are high blood pressure, heart attack and
stroke and
ultimately death. As long as we have plenty of NO, as can be supplied
by the arginine in
Ark1?, our blood pressure remains low and we have protection from many
of the
consequences of the aging process.
To date arginine has been shown in animal as well as human trials that
it may be
effective in the following:
3
? Decreasing and reversing atherosclerosis by decreasing intimal
thickening and
monocyte accumulation 9,10,11,12,13,14
? Restore normal endothelial function in hypercholesterolemia
14,15,16,17,18,19,20,21
? Reversing consequences of coronary artery disease
22,23,24,25,26,27,28,29,30
? Decreasing cholesterol and triglycerides 32
? Improves walking distance in peripheral vascular disease
31,33,34,35,36
? Improves pain in interstitial cystitis 37,38
? Prolonged administration of arginine reverses adverse effects of
high blood
pressure 39,40,41,42
? Decreases high blood pressure 43
? Decreases post operative infection and length of stay 44
? Increases human growth hormone 45,46,47,48,49,50,116
? Improves outcome after bypass surgery 51
? Improves sexual function 52
? Improves exercise tolerance 53,54
? Improves renal function 55,56,57,58,59,60
? Improves glucose uptake in muscle cells 61
? Improves asthma 61,62,63,64,65,66
? Improves cell mediated immunity 67,68,69,70,71
? Improves pituitary responsiveness and modulates hormonal control
72,73,74
? Improves muscle performance 75
? Improves diabetes and reverses damage 76,77,78,79
? May prevent diabetes 78
? Reduces blood clots and strokes 80,81,82
? Helps prevent restenosis after angioplasty and bypass 83,84,85
? Helps prevent post surgical damage after intestinal manipulation 86
? May improve irritable bowel syndrome 87
? Improves osteoporosis 88
? May improve prostate function 89
? May give protection against size of heart attack 90
? Helps protect in cardiac transplants 91,92
? Improve scleroderma 93
? Improve sickle cell disease 94
? Prevent pre-eclampsia 95
? Improves exercise capacity in pulmonary hypertension 96,117,118
? Improves wound healing 97,98,99
? Reduces ulcers 101,102
? Improves peripheral vascular disease 103,104
? Improves outcome in sepsis 105
? Improves heart failure 106
? Improves outcome of cancer treatment 107,108
? Improve alzheimer's 109,110,111,112
? Improves memory and cognitive functions 113,114,115
? L-arginine has been shown to safe in the above studies as well as
others 100,116
To summarize, arginine by virtue of being a safe and natural Nitric
Oxide donor can be an
extremely significant factor in the treatment and reversal of most
major diseases.
4
The impact of the arginine in Ark1? on preventative healthcare and
anti-aging is
profound, not to mention that it is a safe and effective replacement
for the Viagra? type
drugs.
References
1. Fried R, Merrell WC. The Arginine Solution. New York, NY. Warner
Books, 1999.
2. Coffee, C J: Metabolism. Madison, Ct: Fence Creek Publishing,
1998.pp388-389
3. Catt KJ: Molecular Mechanisms of Hormone Action. In Endocrinology
and Metabolism, 3rd ed. Edited by Felig P,
Baxter JD, Frohman LA. New York, NY: McGraw-Hill, 1995, pp 138-139
4. Gerhard M, et al. Aging progressively impairs endothelium-dependent
vasodilation in forearm resistance vessels of
humans. Hypertension 1996 Apr;27(4):849-53
5. Toprakci M, et al. Age-associated changes in nitric oxide
metabolites, nitrite and nitrate. Int J Clin Lab Res
2000;30(2):83-5
6. Sakuma I, et al. Identification of arginine as a precursor of
endothelium-derived relaxing factor. Proc Natl Acad Sci
USA 1988 Nov;85(22):8664-7
7.Vallance P, Moncada S. Nitric Oxide-from mediator to medicines. J R
Coll Physicians Lond 1994 May-Jun;28 (3):
209-219
8. Kam PC, Govender G. Nitric oxide: basic science and clinical
applications. Anaesthesia 1994 Jun;49(6): 515-21
9. Sinha G. Viagra: ups and downs. Popular Science 2000 July: page 35
10. Boger RH, Bode-Boger SM, Kienke S, et al. Dietary L-arginine
decreases myointimal cell proliferation and vascular
monocyte accumulation in cholesterol-fed rabbits.Atherosclerosis 1998
Jan;136(1) 67-77
11. Cheng JW, Balwin SN. L-Arginine in the management of
cardiovascular diseases. Ann Pharmacother 2001
Jun;35(6):755-64
12. Tentolouris C, Tousoulis D, et al. L-Arginine in coronary
atherosclerosis. Int J Cardiol 2000 Sep 15;75(2-3):123-8
13. Wang B, Ho HV, et al. Regression of atherosclerosis. Circulation
1999;99(9):1236-41
14. Boger RH, Bode-Boger SM, et al. Dietary L-arginine reduces the
progression of atherosclerosis in cholesterol fed
rabbits: comparison with lovastatin. Circulation 1997; 96(4):1282-90
15. Schuschke DA, Miller FN, Lominadze DG, Feldhoff RC. L-arginine
restores cholesterol-attenuated micro vascular
responses in the rat cremaster. Int J Micricirc Clin Exp 1994 Jul-Aug;
14(4): 204-11
16. Orlandi A, Marcellini M Spagnoli LG. Aging influences development
and progression of earl aortic atherosclerosis
lesions in cholesterol-fed rabbits. Arterioscler Thromb Vasac Biol
2000 Apr;20
17. Chong PH, Bachenheimer BS. Current, New and future treatments in
dyslipidemia and atherosclerosis. Drugs
2000 Jul;60(1):55-93
18. Phivthong-ngam L, Bode-Boger SM, Boger RH, et al. Dietary L-
arginine normalizes endothelial induced vascular
contractions in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1998
Aug;32(2): 300-7
19. Maxwell AJ, Anderson B Zapien MP, Cooke JP. Endothelial
dysfunction in hypercholesterolemia is reversed by:
nutritional product designed to enhance nitric oxide activity.
Cardiovasc Drugs Ther 2000 Jun;14(3):309-16
20. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves
endothelial-dependent dilation in
hypercholesterolemic young adults. J Clin Invest 1996 April; 97(8):
1989-94
21. Cooke JP, Dzau J, Creager A. Endothelial dysfunction in
hypercholesterolemia is corrected by L-arginine. Basic
Res Cardiol 1991; 86 Suppl 2: 173-81
22. Fraser GE. Diet and coronary heart disease: beyond dietary fats
and low-density-lipoprotein cholesterol. Am J Clin
Nutr 1994 May;59(5 Suppl) 1117s-1142sand atherosclerosis. Drugs 2000
Jul;60(1):55-93
23. Quyyumi AA. Does acute improvement of endothelial dysfunction in
coronary arterydisease improve myocardial
ischemia? J Am Coll Cardiol 1998 Oct;32(4):904-11
24. Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine
supplementation improves small vessel coronary
endothelial function in humans. Circulation 1998 Jun 2;97(21):1648-9
25. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of
supplemental oral L-arginine on exercise capacity
in patients with stable angina pectoris. Am J Cardiol 1997 Aug 1;
80(3):331-3
26. Desrois M, Sciaky M, Lan C, et al. L-arginine during long-term
ischemia: effects on cardiac function, energetic
metabolism and endothelial damage. J Heart Lung Transplant 2000 April;
19(4): 367-76
27. Quyyumi AA, Dakak N, Dodati JG, et al. Effect of L-arginine on
human coronary endothelium-dependent and
physiologic vasodilation, J AM Coll Cardiol 1997 Nov 1; 30(5):1220-7
28. Egashira K, et al. Effects of L-arginine supplementation on
endothelium-dependent coronary vasodilation in
patients with angina pectoris and normal coronary arteriograms.
Circulation 1996;94(2):130-4
29. Tentoluris C, et al. L-arginine in coronary atherosclerosis. Int J
Cardiol 2000 Sep15;75(2-3):123-8
5
30. Tretjakovs P, Kalnins U, Dabina I, et al. Plasma HDL-cholesterol
has an effect on nitric oxide production and
arachidonic production in the platelet membranes of coronary artery
disease patients without LDLhypercholesterolemia.
Med Sci Monitor 2000 May- Jun;6(3):507-11
31. Bode-Boger SM, Boger RH, Galland A, Tsikas D Frolich JC. L-
arginine induced vasodilatation in healthy humans:
pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998
Nov; 46(5): 489-97
32. Khedara A, Kawai Y Kayashita J Kato N. Feeding rats the nitric
oxide synthase inhibitor, L-N(omega) nitroarginine,
elevates serum triglycerides and cholesterol and lowers hepatic fatty
acid oxidation. J Nutr 1996 Oct;126(10):2563-
7
33. Boger RH, Bode-Boger SM, Theil W, et al. Restoring vascular nitric
oxide formation by L-arginine improves
symptoms of intermittent claudication in patients with Peripheral
arterial occlusive disease. J Am Col Cardiol 1998
Nov;32(5):1336-44
34. Maxwell AJ, Anderson BE Cooke JP. Nutritional therapy for
peripheral artery disease. Vasc Med 2000;5(1):11-19
35. Hiatt WR. New treatment options in intermittent claudication: the
US experience. Int J Clin Pract Suppl 2001
Apr;(119):20-27
36. Creager MA. Medical management of peripheral artery disease.
Cardiol Rev 2001 Jul-Aug;9(4):238-45
37. Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE. A
randomized double-blind study of oral L-arginine for
treatment of interstitial cystitis. J Urol 1999 Feb; 161(2):558-65
38. Cartledge JJ, Davies AM, Eardley I. A randomized double-blind
placebo-controlled crossover trial of the efficacy of
L-arginine in the treatment of interstitial cystitis. BJU Int 2000
Mar; 85(4):421-6
39. Sisic D, Francishetti A, Frolich ED. Prolonged L-arginine on
cardiovascular mass and myocardial hemodynamics
and collagen in aged spontaneously hypertensive and normal rats.
Hypertension 1999 Jan;33(1 Pt 2):451-5
40. Higashi Y, et al. Effects of L-arginine infusion on renal
hemodynamics in patients with mild hypertension.
Hypertension1995;25(4):898-902
41. Hishikawa K, et al. Role of L-arginine-nitric oxide pathway in
hypertension. J Hypertens 1993 Jun; 11(6):639-45
42. Dominiczak AF, Bohr DF. Nitric oxide and its' putative role in
hypertension. Hypertension 1995;25(6):1202-11
43. Nakaki T, et al. L-arginine induced hypotension. Lancet 1990Oct
20; 336(8721):1016-7
44. Braga M, Gianotti L Raedelli G, et al. Perioperative
immunonutrition in patients undergoing cancer surgery: results
of a randomized double-blind phase 3 trial. Arch Surg 1999 Apr;134(4):
428-33
45. Ghigo E, Aimaretti G, Cornelli G, et al. Diagnosis of GH
deficiency in adults. Growth Hormone IGF Res 1998 Feb;8
Suppl A:55-8
46. Wideman L Weltman JY, Patrie JY, et al. Synergy of L-arginine and
GHRP-2 stimulation of growth hormone in men
and women: modulation by exercise. Am J Physiol Regul Integr Comp
Physiol 2000 Oct;279(4):R1467-77
47. Gianotti L, Macario M, Lanfranco F, et al. Arginine counteracts
the inhibitory effect of recombinant human insulinlike
growth factor I on the somatotroph responsiveness to growth hormone-
releasing hormone in humans. J Clin
Endocrinol Metab 2000 Oct;85(10):3604-8
48. Mauras N, Walton P, Nicar M, et al. Growth hormone stimulation
testing in both short and normal statured children.
Pediatr Res 2000 Nov;48(5):579-80
49. Ghigo E, Arvat E, Gianotti L, et al. Hypothalamic growth hormone-
insulin-like growth facto-1 axis across the human
life span. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1493-502
50. Korbonits M, Kaltsas G, Perry LA, et al. The growth hormone
secretagogue hexarelin stimulates the hypothalamopituitary-
adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999
Jul;84(7):2489-95
51. Wallace AW, Ratcliffe MB, Galindez D, Kong JS. L-arginine infusion
dilates coronary vasculature in patients
undergoing coronary bypass surgery Aenesthesiology 1999 Jun;90(6):
1577-8
52. Chen J, Wollman Y, Chernichovsky T, et al. Effect of high dose
nitric oxide donor L-arginine in men with organic
erectile dysfunction. BJU Int 1999 Feb;83(3):269-73
53. Kobayashi N, Nakamura M, Hiramori K. Effects of infusion of L-
arginine on exercise-induced myocardial ischemic
changes and capacity to exercise of patients with stable angina
pectoris. Coron Artery Dis 1999 Jul;10(5):321-6
54. Bednarz B, Wolk R, Chamiec T, et al. Effects of oral L-arginine
supplementation on exercised induced QT
dispersion and exercise tolerance in stable angina pectoris.Int J
Cardiol 2000 Sep 15; 75(2-3): 205-10
55. De Nicola L, Bellizzi V, Minutolo R, et al. Randomized, double-
blind, placebo controlled study of arginine
supplementation in chronic renal failure. Kidney Int 1999 Aug;56(2):
674-84
56. Watanabe G, Tomiyama H, Doba N. Effects of oral L-arginine on
renal function in patients with heart failure. J
Hypertens 2000 Feb;18(2):229-34
57. Kelly BS, Alexander JW Dreyer D, et al. Oral arginine improves
blood pressure in renal transplant and
hemodialysis patients. J Parenter Enteral Nutr 2001 Jul-Aug; 25(4):
194-202
58. Efron DT, Barbul A. Arginine and nutrition in renal disease. J Ren
Nutr 1999 Jul;9(3):142-4
59. Reckelhoff JF, et al. Long-term dietary supplementation with L-
arginine prevents age related reduction in renal
function. Am J Physiol 1997 Jun; 272(6 Pt 2):1768-74
60.Reyes AA, Purkerson ML, Karl L, Klahr S. Dietary supplementation
with L-arginine ameliorates the progression
of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis
1992 Aug; 20(2):454-5
61. Bradley SJ, Kingwell BA, McConell GK. Nitric oxide synthase
inhibition reduces leg glucose uptake but not blood
flow during dynamic exercise in humans. Diabetes 1999 Sep; 48(9):
1815-21
6
62. De Gouw HW, Verbruggen MB, Twiss IM, Sterk PJ. Effect of oral L-
arginine on airway hyper-responsiveness to
histamine in asthma. Thorax 1999 Nov;54(11):1033-5
63. De Gouw HW, Marshall-Partridge SJ, et al. Role of nitric oxide in
the airway response to exercise in healthy and
asthmatic subjects. J Appl Physiol 2001 Feb;90(2):586-92
64. Boer J, et al. Role of L-arginine deficiency of nitric oxide and
airway hyperreactivity after allergen-induced early
asthmatic reaction in guinea-pigs. Br J Pharmacol 1999 Nov;128(5):
1114-20
65. Blease K, Kunkel SL, Hogaboam CM. Acute inhibition of nitric oxide
exacerbates airway hyperresponsiveness,
eosinophilia and C-C chemokine generation in a murinemodel of fungal
asthma. Inflamm Res 2000 Jun; 49(6):297-
304
66. Du J, Cui D, Tian D. [ The role of nitric oxide in the
pathogenesis of asthma.] [ Full text in Chinese] Zhonghua Jie
He He Hu Xi Za Zhi 1997 Jun;20(3):153-6
67. Gionotti L, Braga M, Fortis C, et al. A prospective, randomized
clinical trial on perioperative feeding with an
arginine-, omega-3 fatty acid-, and RNA enriched enteral diet: effect
on host response and nutritional status. J
Parenter Enteral Nutr1999 Nov- Dec;23(6):314-20
68. Efron D, Barbul A. Role of arginine in immunonutrition. J
Gastroentol 2000;35 Suppl 12:20-3
69.Lewis B, Langkamp-Henken B. Arginine enhances in vivo immune
responses in young, adult and aged mice. J
Nutri 2000;130(7):1827-30
70. Mannick JB, et al. Nitric oxide produced by human B lymphocytes
inhibits apoptosis and Epstein-Barr virus
reactivation. Cell 1994 Dec 30;79(7):1137-46
71.Ochoa JB, et al. Effects of L-arginine on the proliferation of T-
lymphocyte subpopulations. J Parenter Enteral Nutr
2001 Jan- Feb;25(1):23-9
72. di Luigi L, Guidetti L, Pigozzi F, et al. Acute amino acid
supplementation enhances pituitary responsiveness in
athletes. Med Sci Sports Exerc 1999 Dec;31(12):1748-54
73. Lawecki J et al. Serum insulin, pancreatic glucagons and growth
hormone levels in response to intravenous
infusion of L-arginine in patients with recently detected juvenile
diabetes. Pol Med Sci Hist Bull 1976 Apr-
Jun;15(2):177-82
74. Valcenti S, et al Biphasic effect of nitric oxide on testosterone
and cyclic GMP productionby purified rat Leydig cells
cultured in vivo. Int J Androl 1999 Oct; 22(5):336-41
75. Stevens BR, Godfrey MD, Kaminski TW, Braith RW. High intensity
dynamic human muscle performance enhanced
by a metabolic intervention. Med Sci Sports Exerc 2000 Dec;32(12):
2102-8
76. Piatti PM, Monti LD, Valsecchi G, et al. Long term oral L-arginine
administration improves peripheral and hepatic
insulin sensitivity in type 2 diabetes. Diabetes Care 2001 MAY;24(5):
875-80
77. Giugliana D, et al. Vascular effects of acute hyperglycemia are
reversed by L-arginine. Circulation 1997;
95(7):1783-90
78. Mohan IK, Cas UN. Effects of L-arginine-nitric oxide system on
chemical induced diabetes mellitus. Free Radic Biol
Med 1998 Nov 1;25(7):757-65
79. Mendez JD, Balderas F. Regulation of hyperglycemia and
dyslipidemia by exogenous L-arginine in Diabetic rats.
Biochemie 2001 May;83(5):453-8
80. Kaposzta Z, et al. L-arginine and S-nitroglutathione reduce
embolization in Humans. Circulation
2001;103(19):2371-75
81. Bode-Boger SM, Boger RH, et al. Differential inhibition of human
platelet aggregation and thromboxane A 2
formation by L-arginine in vivo and in vitro. Arch Pharmacol 1998;
357:143-150
82. Wolf A, et al. Dietary L-arginine supplementation normalizes
platelet aggregation in hypercholesterolemic humans.
J Am Coll Cardiol 1997 Mar 1; 29(3):479
83. Le Yorneau T, Van Belle E, Corseaux D, et al . Role of nitric
oxide in re-stenosis after experimental balloon
angioplasty in the hypercholesterolemic rabbit. J Am CollCardiol 1999
Mar;33(3):876-82
84. Janero DR, Ewing JF. Nitric Oxide and Postangioplasty re-stenosis:
Pathologicalcorrelates and therapeutic
potential. Free Radic Biol Med 2000 Dec 15;29(12):1199-221
85. Severin P, et al. Local intramural delivery of l-arginine enhances
nitric oxide generation and inhibits lesion
formation after balloon angioplasty. Circulation 1997;95(7):1863-9
86. Thomas S, Ramachandran A, Patra S, et al. Nitric oxide protects
the intestine from the damage induced by
laparotomy and gut manipulation. J Surg Res 2001 Jul;99(1):25-32
87.Sahin AS, Atalik KE, Gunel E, Dogan N. Nonadrenergic,
noncholinergic responses of the human colon smooth
muscle and the role of K+channels in these responses.. Methods Find
Exp Clin Pharmacol 2001 Jan-Feb;23(1):13-
7
88. Fini M, et al. Effect of l-lysine and L-arginine on primary
osteoblast cultures from normal and osteopenic rats
Biomed Pharmacother 2001 May;55(4):213-21
89. Aikawa K, Yokota T, et al. Endogenous nitric oxide-mediated
relaxation and nitrinergic innervation in the rabbit
prostate: the change with aging. Prostate 2001 Jun 15;48(1):40-6
90. Suematsu Y, Ohtsuka T, et al. L-Arginine given after ischemic
preconditioning can enhance cardioprotection in
isolated rat hearts. Eur J Cardiothorac Surg 2001, Jun;19(6):873-9
7
91. Koglin J. Pathogenetic mechanisms of cardiac allograft
vasculopathy-impact of nitric oxide. Z Kardiol 2000;89
Suppl 9:IX/24-7
92. Kown MH, Van Der Steenhoven T, Uemura S, et al. L-Arginine polymer
mediated inhibition of graft coronary artery
disease after cardiac transplantation. Transplantation 2001 June
15;71(11):1542-8
93. Freedman RR, Girgis R, Mayers MD. Acute effect if nitric oxide on
Raynaud's phenomenon in scleroderma. Lancet
1999 Aug 28:354;739
94. Morric CR, Kuypers FA, et al. Patterns of arginine and nitric
oxide in patients with sickle cell disease with vasoocclusive
crisis and acute chest syndrome. J Ped Hemat/Onc 2000 Nov-Dec;22(6):
515-20
95. Kumar CA, Das UN. Lipid peroxides, antioxidants and nitric oxide
in patients with pre-eclampsia and essential
hypertension. Med Sci Monitor 2000 Sep-Oct;6(5):901-7
96. Nagaya N, Uematsu M, et al. Short term oral administration of l-
arginine improves hemodynamics and exercise
capacity in patients with precapillary pulmonary hypertension. Am J
Resp Crit Care Med 2001 April;163(4):887-91
97. Barbul A, et al. Arginine enhances wound healing and lymphocyte
immune responsesin humans. Surgery 1990
Aug;108(2):331-6; discussion 336-7
98. Kirk SJ, et al Arginine stimulates wound healing and immune
function in elderly humans. Surgery 1993
Aug;114(2):155-9; discussion 160
99. De-Souza DA, Greene LJ. Pharmacological nutrition after burn
injury. J of Nutri 1998 May;128(5):797-803
100.Blum A, Cannon RO, Costello R, et al. Endocrine and lipid effects
of oral L-arginine treatment in healthy
postmenopausal women. J Lab Clin Med 2000 Mar;135(3):231-7
101.Ohta Y, Nishida K., Protective effect of l-arginine against stress-
induced gastric mucosal lesions in rats and its
relation to nitric acid-mediated inhibition of neutrophil
infiltration. Pharmacal Res 2001 Jun;43(6):535-41
102.Khattab MM, Gad MZ, Abdallah D. Protective role of nitric oxide in
indomethacin- induced gastric ulceration by a
mechanism independent of gastric acid secretion. Pharmacol Res 2001
May;43(5):463-7
103.Calver A, Collier J, Vallance P. Dilator actions of arginine in
human peripheral vasculature. Clin Sci 1991
Nov;81(5):695-700
104.Bode-Boger SM, Boger RH,et al. L-arginine induces nitric oxide-
dependent vasodilation in patients with critical limb
ischemia. A randomized, controlled study. Circulation 1996 Jan 1;
93(1):85-90
105.Vallet B. Microthrombosis in sepsis. Minerva Anestesiol 2001 Apr;
67(4):298-301.
106.Hambrecht R, et al. Correction of endothelial dysfunction in
chronic heart failure: additional effects of exercise
training and oral L-arginine supplementation. J Am Coll Cardiol 2000
Mar 1; 35(3):706-13
107.Heys SD, et al. Dietary supplementation with L-arginine:
Modulation of tumor infiltrating lymphocytes in patients
with colo-rectal cancer. Br J Surg 1997 Feb;84(2):238-41
108.Brittenden J, et al. Dietary supplementation with L-arginine in
patients with breast cancer(> 4cm.) receiving multimodality
treatment: report of a feasibility study. Br J Cancer 1994 May;69(5):
918-21
109.McCarty MF. Vascular nitric oxide, sex hormone replacement, and
fish oil may help to prevent Alzheimer's disease
by suppressing synthesis of acute-phase cytokines. Med Hypotheses 1999
Nov;53(3):369-74
110.Tarkowski E, et al. Intrathecal release of nitric oxide in
Alzheimer's disease and vascular dementia. Dement Geriatr
Cogn Disord 2000 Nov- Dec;11(6):322-6
111.de la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a
microvascular disorder: the role of constitutive
nitric oxide. Brain Res Brain Res Rev 2000 Dec;34(3):119-36
112.Kuiper MA, et al. Decrease cerebrospinal fluid nitrate levels in
Parkinson's disease, Alzheimer's disease and
multiple system atrophy patients. J Neurol Sci 1994 Jan; 121(1):46-9
113.Pautler EL. The possible role and treatment of deficient
microcirculation regulation in age-associated memory
impairment. Med Hypotheses 1994 Jun;42(6):363-6
114.Pandhi P, Balakrishnan S. Cognitive dysfunction induced by
phenytoin and valproate in rats: effect of nitric oxide.
Indian J Physiol Pharmacol 1999 Jul; 43(3):378-82
115.Pendergast MA, et al. Nitric oxide synthase inhibition impairs
delayed recall in mature monkeys. Pharmacol
Biochem Behav 1997 Jan;56(1):81-7
116.Fideieff HL,et al. Reproducibility and safety of the arginine test
in normal adults.Medicina (B Aires) 1999;
59(3):249-53
117.Fagan JM, et al. L-arginine reduces right heart hypertrophy in
hypoxia-induced pulmonary hypertension. Biochem
Biophys Res Commun 1999 Jan 8; 254(1):100-3
118.Nitric oxide and pulmonary hypertension. Coron Artery Dis 1999
Jul; 10(5):287-94

This is what I was Saying.....................................
Now are you interested in changing lives???????????????????